You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Discovery of a Small Molecule Antagonist of the Parathyroid Hormone Receptor by Using an N-Terminal Parathyroid Hormone Peptide Probe
Percy H. Carter, Rui-Qin Liu, William R. Foster, Joseph A. Tamasi, Andrew J. Tebben, Margaret Favata, Ada Staal, Mary Ellen Cvijic, Michele H. French, Vanessa Dell, Donald Apanovitch, Ming Lei, Qihong Zhao, Mark Cunningham, Carl P. Decicco, James M. Trzaskos and Jean H. M. Feyen
Proceedings of the National Academy of Sciences of the United States of America
Vol. 104, No. 16 (Apr. 17, 2007), pp. 6846-6851
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/25427471
Page Count: 6
You can always find the topics here!Topics: Receptors, Molecules, Agonists, Inhibitory concentration 50, Bones, Cell lines, Calcium, Antagonists, Molecular probes, RNA
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Once-daily s.c. administration of either human parathyroid hormone (PTH)-(1-84) or recombinant human PTH-(1-34) provides for dramatic increases in bone mass in women with postmenopausal osteoporosis. We initiated a program to discover orally bioavailable small molecule equivalents of these peptides. A traditional high-throughput screening approach using cAMP activation of the PTH/PTH-related peptide receptor (PPR) as a readout failed to provide any lead compounds. Accordingly, we designed a new screen for this receptor that used a modified N-terminal fragment of PTH as a probe for small molecule binding to the transmembrane region of the PPR, driven by the assumption that the pharmacological properties (agonist/antagonist) of compounds that bound to this putative signaling domain of the PPR could be altered by chemical modification. We developed DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the PPR, and characterized its activity in ex vivo and in vivo assays of bone resorption. In addition, we studied its ability to initiate gene transcription by using microarray technology. Together, these experiments indicated that the highly modified 14 amino acid peptide induces qualitatively similar biological responses to those produced by PTH-(1-34), albeit with lower potency relative to the parent peptide. Encouraged by these data, we performed a screen of a small compound collection by using DPC-AJ1951 as the ligand. These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model.
Proceedings of the National Academy of Sciences of the United States of America © 2007 National Academy of Sciences